CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
黏附 G 蛋白偶联受体 F5（ADGRF5）作为癌症免疫反应的设计师
英文原题：The adhesion G protein-coupled receptor F5 (ADGRF5) as an architect of immune response in cancers.
查看英文原题
The adhesion G protein-coupled receptor F5 (ADGRF5) as an architect of immune response in cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
黏附G蛋白偶联受体F5（ADGRF5）已成为细胞稳态和疾病发病机制的关键调节因子。近期研究揭示了其在驱动内在癌细胞侵袭性以及调控肿瘤微环境中的双重作用，凸显了其在免疫治疗策略中尚未开发的潜力。本综述深入探讨了ADGRF5表达和信号传导对癌细胞和免疫细胞的影响，强调了ADGRF5在癌症相关免疫中的关键作用。此外，基于近期实验数据，本文阐述了ADGRF5特性的转化应用方面，为免疫肿瘤学治疗领域提供了未来展望。
展开英文摘要原文
The adhesion G protein-coupled receptor F5 (ADGRF5) has emerged as a critical regulator of cellular homeostasis and disease pathogenesis. Recent investigations have revealed its dual role in driving intrinsic cancer cell aggressiveness, while orchestrating the tumor microenvironment, highlighting its untapped potential in immunotherapeutic strategies. This review provides insights into the impact of ADGRF5 expression and signaling on cancer and immune cells, underlining the essential role of ADGRF5 in cancer-related immunity.
Furthermore, based on recent experimental data, the translational aspects of ADGRF5 properties are elaborated, providing a future perspective within the therapeutic area of immunooncology.
论文信息
- 作者
- Jacenik D
- 单位
- University of Lodz, Faculty of Biology and Environmental Protection, Department of Cytobiochemistry, Lodz, Poland. Electronic address: damian.jacenik@biol.uni.lodz.pl.Poland
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Biochimica et biophysica acta. Reviews on cancer2026 Sep
- 原文标识
- PubMed 42437594 · DOI 10.1016/j.bbcan.2026.189662